CHESS Health Rewards Engine: A Better Way to Fight Stimulant Crisis Across Colorado
Contingency Management Program Launched across 13 Locations in 4 Weeks
Rochester, New York, June 25, 2025 (GLOBE NEWSWIRE) -- CHESS Health is partnering with Porch Light HealthⓇ (PLH) to offer its innovative, automated contingency management Rewards Engine for treating individuals with substance use disorder (SUD). PLH's program, called Porch Light Rewards, is being piloted as a tool to motivate patients to stay in Medication for Addiction Treatment (MAT), engage in counseling, and abstain from substance use.
As a multi-location provider with over 60 locations, dozens of staff, and thousands of patients, PLH sought a contingency management platform that was simple and reliable to meet its outcome and retention goals. Working closely with the CHESS Health team, PLH successfully launched the Rewards Engine pilot across thirteen Colorado locations in just four weeks—demonstrating the platform's ease of implementation and rapid deployment capabilities.
The CHESS Health Rewards Engine streamlines contingency management for providers by digitizing the incentive protocol, offering a user-friendly web dashboard for staff, automatically delivering rewards to a reloadable debit card provided to each patient, utilizing text messages to deliver positive reinforcements, and ensuring programs stay within budget with zero errors. In addition, thorough and accurate tracking of reward distribution was critical, as six sources, including opioid settlement dollars, funded the solution. CHESS Health's Rewards Engine can seamlessly manage this level of complex reporting.
In the first six weeks following the program launch, PLH has enrolled over 125 patients in the program, and feedback from both patients and staff has been overwhelmingly positive. Engagement and outcomes are tracked using the CHESS platform; initial data on patient retention improvements will be available in late June. Outcomes will be tracked over the next 12 months.
Steve Carleton, LCSW, CAS-Chief Clinical Officer at PLH, brings 20 years of SUD treatment experience. "Contingency management is hands down the best and most effective treatment for individuals with a stimulant use disorder. There are no other medical or behavioral treatments that come close to contingency management outcomes in this population," noted Carleton. "However, the biggest barrier has traditionally been the administrative burden—tracking eligibility, managing rewards, maintaining documentation, and coordinating staff efforts pulls clinical teams away from patient care. CHESS Health's Rewards Engine eliminated these burdens by automatically handling criteria verification, documentation, and reward distribution, allowing our clinicians to focus on treating patients."
'Contingency management works, but without automation, it's really hard for providers to implement and maintain,' said Hans Morefield, CEO of CHESS Health. 'We're pleased to be making effective contingency management easy and successful for Porch Light Health.'
About Porch Light HealthPorch Light Health's mission (formerly Front Range Clinic), is to provide low-barrier, high-access, quality medical addiction treatment to those affected by substance use disorders and related medical conditions. Porch Light Health offers comprehensive outpatient addiction treatment services for substance use disorders, including Opioids, Alcohol, Stimulants, Sedatives, as well as nicotine and cannabis use. In addition to evidence-based medications for addiction treatment, PLH offers psychiatry, therapy, and treatment for infectious disease and other comorbidities. For more information about Porch Light Health and its comprehensive addiction treatment services, call 866-MAT-STAT or visit https://porchlighthealth.com.
About CHESS HealthCHESS Health is a leading provider of evidence-based digital behavioral health solutions backed by peer support. These tools empower providers, health plans, and public sector organizations to address the substance use disorder crisis by enhancing prevention, facilitating care coordination, and improving adherence to care plans and treatment retention, ultimately resulting in better health outcomes. For more information, visit www.chess.health.
CONTACT: Meg Miller CHESS Health 4144699702 mmiller@chess.health
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
Amesite's HIPAA Compliant NurseMagic™ App Now Operates in 16 Languages — Expanding Access to AI-Powered Charting for Nearly 1 Million U.S. Nurses
By GlobeNewswire Published on June 26, 2025, 01:43 IST DETROIT, June 25, 2025 (GLOBE NEWSWIRE) — Amesite Inc. (NASDAQ: AMST), a leading developer of AI-powered enterprise solutions, today announced that its flagship app, NurseMagic™, now supports charting in 16 languages. This major enhancement is designed to address a key barrier to success for nearly 1 million nurses in the U.S. who speak English as a second language (ESL) — accounting for 19.2% of the nursing workforce — and to chart more efficiently and with greater confidence. This multilingual capability positions Amesite to meet immediate market needs. Markets now able to leverage the platform include: ESL nurses in the United States : Nearly 20% of U.S. nurses have English as a Second Language (ESL) : Nearly 20% of U.S. nurses have English as a Second Language (ESL) International healthcare systems treating U.S. patients : There are over 6.5 Million nurses in the top 10 medical tourist destinations for U.S. patients alone. : There are over 6.5 Million nurses in the top 10 medical tourist destinations for U.S. patients alone. Private clinics in multilingual regions: The private sector provides nearly 40% of all healthcare in PAHO, AFRO, and WPRO regions, 57% in SEARO, and 62% in EMRO. Madison Bush, Director of Corporate Operations, said, 'This rollout reflects our disciplined approach to targeting segments with clear, documented needs — including the nearly one in five nurses in the U.S. who speak English as a second language. By addressing the needs of this workforce, who must document in English, we're positioned to capture value domestically and expand internationally.' Sai Nittala, Senior AI Manager, said, 'NurseMagic™ V3.0 delivers healthcare charting solutions that outperform generic, off-the-shelf AI tools. Unlike many unregulated or non-integrated solutions, NurseMagic™ is designed for seamless integration into critical healthcare workflows — where compliance, accuracy, and efficiency are essential. Our multilingual capability underscores our ability to scale rapidly while meeting real-world needs.'' Dr. Ann Marie Sastry, Founder & CEO, said, 'We have growing B2B traction following our launch of enterprise administration tools, and are also supporting B2C growth in new segments that prepare us for global expansion. As reported in our Q3 2025 10‑Q, we achieved a 2.4× quarter-on-quarter revenue increase while continuing to cut operating expenses. We believe we're on track for further revenue growth and cost efficiencies in coming quarters.' NurseMagic™ is Now Available In: English, Chinese, Hindi, Spanish, French, Portuguese, Russian, Indonesian, German, Japanese, Korean, Turkish, Italian, Ukrainian, Dutch, Swedish. Amesite recently announced a 2.4x quarter-over-quarter revenue increase in its 10-Q filing, driven by rapid adoption of its NurseMagic™ platform and improvements in operating efficiency. The company also launched a higher-priced enterprise tier in response to growing B2B demand for more capacity. In April, Amesite reported that NurseMagic™ meets HIPAA requirements for individual users and enterprises, enabling secure documentation of protected health information across all user types. About Amesite Inc. Amesite (NASDAQ: AMST) is an AI-driven company with an immediate aim to transform the $330 billion home and healthcare segments. Its flagship product, NurseMagic™, streamlines documentation for nurses and caregivers, reducing the time required from 20 minutes to just 20 seconds. NurseMagic™ is used by over 100 professions to improve care, enhance operational efficiency and improve financial performance. Built on proprietary AI trained on industry-specific data, NurseMagic meets HIPAA regulations while improving accuracy and efficiency. The platform serves B2B and B2C users across 50 states and 21 countries, offering seamless integration into healthcare workflows and translations to over 50 languages. Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning the Company, the Company's planned online machine learning platform, the Company's business plans, any future commercialization of the Company's online learning solutions, potential customers, business objectives and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'should,' 'would,' 'expect,' 'plan,' 'believe,' 'intend,' 'look forward,' and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement. Risks facing the Company and its planned platform are set forth in the Company's filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations [email protected] Sources Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
an hour ago
- Business Upturn
Coalition to Improve Access to Cancer Care Applauds Reintroduction of the Cancer Drug Parity Act
WASHINGTON, June 25, 2025 (GLOBE NEWSWIRE) — The Coalition to Improve Access to Cancer Care (CIACC) applauds the reintroduction of the Cancer Drug Parity Act, bipartisan legislation that would require group and individual health insurance plans to cover oral and self-administered anticancer medications on terms no less favorable than those covering intravenous (IV), injected, or port-administered therapies. The bill aims to eliminate outdated insurance practices that make it more expensive for patients to access self-administered cancer treatments, even when those treatments are the most appropriate or only option available. 'Patients should not face higher costs simply because their cancer treatment comes in a pill instead of an IV,' said Danielle Doheny, Director of Public Policy and Advocacy at the International Myeloma Foundation, who leads the Coalition to Improve Access to Cancer Care. 'This legislation ensures that treatment decisions are guided by what is medically best for the patient and not by outdated insurance structures that create unnecessary financial barriers for patients.' 'The lymphoma community has witnessed incredible advancement in the treatment of the disease through the development of innovative and effective therapies, including oral treatments. The Cancer Drug Parity Act seeks to protect patient access to the cancer treatments prescribed by their doctors; we support the reintroduction of this legislation on behalf of the patients and families we exist to serve,' said Meghan Gutierrez, Chief Executive Officer, Lymphoma Research Foundation. Traditionally, IV cancer drugs are covered under a health plan's medical benefit, often resulting in lower out-of-pocket costs for patients. In contrast, oral and self-administered cancer drugs are typically covered under the pharmacy benefit, where patients may face high copays, coinsurance, or deductibles. The Cancer Drug Parity Act would correct this imbalance by requiring parity in how insurers cover and reimburse cancer treatments, regardless of how they are administered. 'This bill provides us another valuable tool to mitigate the significant and burdensome out-of-pocket medical expenses facing individuals with a cancer diagnosis,' said Joanna Fawzy Doran, Esq., CEO of Triage Cancer. 'Oral therapies are sometimes not only the best option but the only option for a patient, especially those living with metastatic breast cancer. Unfortunately, they remain out of reach for many,' said Molly Guthrie, Vice President of Policy & Advocacy at Susan G. Komen. 'Treatment decisions should be determined by a patient and their provider, not dictated by outdated insurance coverage benefit design. Komen is proud to support the Cancer Drug Parity Act, ensuring breast cancer patients have the ability to choose the best treatment for them without unneeded barriers.' Healthcare providers echo the concern that patients should not face financial hardship simply because the most effective or convenient drug is in pill form. 'As providers, we have seen tremendous progress in cancer treatments, and the Cancer Drug Parity Act would protect patients' access to the treatments their oncologists prescribe. By ensuring that patient cost sharing for oral anticancer drugs is no less favorable than for IV chemotherapy, this bill would help remove one financial barrier to care and ensure patients get the right treatment,' said Robert Mancini, PharmD, BCOP, FHOPA, President of the Hematology/Oncology Pharmacy Association. Jessica MacIntyre, DNP, MBA, APRN, AOCNP®, FAANP, President of the Oncology Nursing Society, emphasized the importance of equitable access to modern therapies: 'The Oncology Nursing Society strongly supports the reintroduction of the Cancer Drug Parity Act. This legislation is crucial in ensuring that patients have equitable access to lifesaving cancer treatments regardless of the administration method. By eliminating the disparity between oral and intravenous cancer drug coverage, we can improve patient outcomes, reduce financial burdens, and advance the overall quality of cancer care. ONS is proud to stand with our coalition partners in advocating for this important bill.' Leading cancer advocacy organizations have also reaffirmed their support. 'The Cancer Drug Parity Act would help protect patients' access to their prescribed cancer treatments. By ensuring that patient cost sharing is no more burdensome for oral anticancer drugs than it is for IV anticancer drugs, the bill would remove one of the many financial barriers to care and help ensure patients get the right treatment at the right time. We strongly support this legislation and urge Congress to pass it as soon as possible,' said Association for Clinical Oncology (ASCO) Board Chair Lynn M. Schuchter, MD, FASCO. The Association of American Cancer Institutes (AACI) includes the Cancer Drug Parity Act among its public policy priorities and supports its reintroduction in Congress. This legislation is critical for eliminating financial barriers and reducing health disparities that limit patients' access to cancer care. Lisa Lacasse, President of the American Cancer Society Cancer Action Network, further underscored the bill's impact: 'Disparities in out-of-pocket costs for oral cancer treatments can impact patient and physician decision-making and can lead to patients forgoing the best treatment for their disease. Many patients prefer, when appropriate, chemotherapies that are available in pill form because it is easier to administer and can allow them to have a better quality of life. The Cancer Drug Parity Act would equalize out-of-pocket costs for cancer drugs, whether they're taken orally or delivered intravenously. We urge Congress to advance this lifesaving, bipartisan legislation.' For lung cancer patients, oral targeted therapies have become a cornerstone of treatment. 'The Cancer Drug Parity Act puts patients first,' said Laurie Ambrose, President and CEO of GO2 for Lung Cancer. 'This legislation would ensure that healthcare plans covering cancer treatments provide equal access to oral therapies at the same out-of-pocket cost as IV, port, or injection treatments. As more lung cancer treatments become available, patients deserve affordable options that allow them to spend less time in clinics and more time living their lives.' 'Over the last 15 years, we've seen remarkable advances in lung cancer treatment, particularly in the development of new oral therapies,' said Andrea Ferris, President and CEO of LUNGevity Foundation. 'We applaud the reintroduction of the Cancer Drug Parity Act, which would improve access to innovative treatments by equalizing cost-sharing between oral and intravenous therapies. Patients should have access to the best possible care without having to worry about outdated insurance practices.' The Coalition to Improve Access to Cancer Care urges Congress to act quickly to pass the Cancer Drug Parity Act. The bill will remove financial barriers to care, support treatment innovation, and bring insurance coverage in line with the way cancer is increasingly treated today. About the Coalition to Improve Access to Cancer Care The Coalition for Improved Access to Cancer Care (CIACC) is a patient-focused organization representing patients, health-care professionals, care centers and industry committed to ensuring cancer patients have equal access to all approved cancer regimes, including (but not limited to) oral and intravenous drugs, injections, surgery, radiation, transplantation, etc. Media Contact Danielle Doheny, International Myeloma Foundation (IMF) Director of Public Policy and AdvocacyPhone: 202-531-7954 Email: [email protected]
Yahoo
2 hours ago
- Yahoo
Amesite's HIPAA Compliant NurseMagic™ App Now Operates in 16 Languages — Expanding Access to AI-Powered Charting for Nearly 1 Million U.S. Nurses
NurseMagic™ V3.0 uniquely addresses the needs of approximately 20% of U.S. nurses in the U.S. with AI-powered charting in their native language DETROIT, June 25, 2025 (GLOBE NEWSWIRE) -- Amesite Inc. (NASDAQ: AMST), a leading developer of AI-powered enterprise solutions, today announced that its flagship app, NurseMagic™, now supports charting in 16 languages. This major enhancement is designed to address a key barrier to success for nearly 1 million nurses in the U.S. who speak English as a second language (ESL) — accounting for 19.2% of the nursing workforce — and to chart more efficiently and with greater confidence. This multilingual capability positions Amesite to meet immediate market needs. Markets now able to leverage the platform include: ESL nurses in the United States: Nearly 20% of U.S. nurses have English as a Second Language (ESL) International healthcare systems treating U.S. patients: There are over 6.5 Million nurses in the top 10 medical tourist destinations for U.S. patients alone. Private clinics in multilingual regions: The private sector provides nearly 40% of all healthcare in PAHO, AFRO, and WPRO regions, 57% in SEARO, and 62% in EMRO. Madison Bush, Director of Corporate Operations, said, 'This rollout reflects our disciplined approach to targeting segments with clear, documented needs — including the nearly one in five nurses in the U.S. who speak English as a second language. By addressing the needs of this workforce, who must document in English, we're positioned to capture value domestically and expand internationally.' Sai Nittala, Senior AI Manager, said, 'NurseMagic™ V3.0 delivers healthcare charting solutions that outperform generic, off-the-shelf AI tools. Unlike many unregulated or non-integrated solutions, NurseMagic™ is designed for seamless integration into critical healthcare workflows — where compliance, accuracy, and efficiency are essential. Our multilingual capability underscores our ability to scale rapidly while meeting real-world needs.'' Dr. Ann Marie Sastry, Founder & CEO, said, 'We have growing B2B traction following our launch of enterprise administration tools, and are also supporting B2C growth in new segments that prepare us for global expansion. As reported in our Q3 2025 10‑Q, we achieved a 2.4× quarter-on-quarter revenue increase while continuing to cut operating expenses. We believe we're on track for further revenue growth and cost efficiencies in coming quarters.' NurseMagic™ is Now Available In: English, Chinese, Hindi, Spanish, French, Portuguese, Russian, Indonesian, German, Japanese, Korean, Turkish, Italian, Ukrainian, Dutch, Swedish. Amesite recently announced a 2.4x quarter-over-quarter revenue increase in its 10-Q filing, driven by rapid adoption of its NurseMagic™ platform and improvements in operating efficiency. The company also launched a higher-priced enterprise tier in response to growing B2B demand for more capacity. In April, Amesite reported that NurseMagic™ meets HIPAA requirements for individual users and enterprises, enabling secure documentation of protected health information across all user types. About Amesite Inc. Amesite (NASDAQ: AMST) is an AI-driven company with an immediate aim to transform the $330 billion home and healthcare segments. Its flagship product, NurseMagic™, streamlines documentation for nurses and caregivers, reducing the time required from 20 minutes to just 20 seconds. NurseMagic™ is used by over 100 professions to improve care, enhance operational efficiency and improve financial performance. Built on proprietary AI trained on industry-specific data, NurseMagic meets HIPAA regulations while improving accuracy and efficiency. The platform serves B2B and B2C users across 50 states and 21 countries, offering seamless integration into healthcare workflows and translations to over 50 languages. Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning the Company, the Company's planned online machine learning platform, the Company's business plans, any future commercialization of the Company's online learning solutions, potential customers, business objectives and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement. Risks facing the Company and its planned platform are set forth in the Company's filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations ir@ Sources in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
